03766oam 2200553I 450 991015318290332120240501163901.01-315-37326-21-315-35590-61-4822-3170-010.1201/9781315373263 (CKB)3710000000960834(MiAaPQ)EBC4748363(OCoLC)966398076(EXLCZ)99371000000096083420180331h20172017 uy 0engurcnu||||||||rdacontentrdamediardacarrierBiosimilar clinical development scientific considerations and new methodologies /edited by Kerry B. Barker, Pfizer, Cambridge, Massachusetts, USA, Sandeep M. Menon, Pfizer, Cambridge, Massachusetts, USA, Ralph B. D'Agostino, Sr., Boston Uni1st ed.Boca Raton :Taylor & Francis,[2017]©20171 online resource (269 pages)Chapman & Hall/CRC Biostatistics SeriesA Chapman and Hall book--title page.1-4822-3169-7 Includes bibliographical references at the end of each chapters and index.1. Biosimilars for drug development : the time is now! / Bo Jin, Sandeep M. Menon, Kerry B. Barker, and Ralph B. D'Agostino -- 2. From isolation to integration : a systems biology approach for the discovery of therapeutic targets and biomarkers / Attila Seyhan and Claudio Carini -- 3. Immunogenicity of biological products : current perspectives and future implications / Candida Fratazzi, Attila Seyhan, and Claudio Carini -- 4. Interchangeability between biosimilar and innovator drug products / Bo Jin, Sandeep M. Menon, Kerry B. Barker, and Steven Ye Hua -- 5. Bridging a new biological product with its reference product /Jianjun (David) Li and Jin Xu -- 6. Accounting for covariate effect to show noninferiority in biosimilars / Siyan Xu, Kerry B. Barker, Sandeep M. Menon, and Ralph B. D'Agostino -- 7. Novel method in inference of equivalence in biosimilars / Siyan Xu, Steven Ye Hua, Ronald Menton, Kerry B. Barker, Sandeep M. Menon, and Ralph B. D'Agostino -- 8. Multiplicity adjustments in testing for bioequivalence / Steven Ye Hua, Siyan Xu, and Ralph B. D'Agostino -- 9. Bayesian methods to assess bioequivalence and biosimilarity with case studies / Steven Ye Hua, Siyan Xu, Kerry B. Barker, Shan Mei Liao, and Shujie Li -- 10. Average inferiority measure and standardized margins to address the issues in biosimilar trials / Gang Li and Weichung Joe Shih -- 11. Bayesian methods for design and analysis of noninferiority trials / Mani Lakshminarayanan and Fanni Natanegara.Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.Chapman & Hall/CRC biostatistics series.BiologicalsDrug developmentMethodologyBiologicals.Drug developmentMethodology.615.1/9Barker Kerry B.Menon Sandeep M.D'Agostino Ralph B.Xu SiyanJin BoFlBoTFGFlBoTFGBOOK9910153182903321Biosimilar clinical development2091161UNINA